University of California, Los Angeles
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
Inclusion Criteria: * Ages 21-60, * Fluent in English * Able to swallow capsules, * Meets for a current major depressive episode or a history of major depressive episodes based on the DSM-5 criteria (American Psychiatric Association, 2013), * Active current depressive symptoms (i.e., scores \>16 on the Hamilton-Depression Rating Scale covering the prior 2 weeks; Hamilton, 1986), * Have an identified support person (i.e., trusted adult friend or relative) who can pick up the individual from UCLA Semel Institute and drive individual home following psilocybin sessions, * For women of child-beari…
Two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later)
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023)
Arctuva estimate
Verify or correct the compensation shown for this listing.